ATE478893T1 - Genetisch hergestellte zellen für therapeutische anwendungen - Google Patents

Genetisch hergestellte zellen für therapeutische anwendungen

Info

Publication number
ATE478893T1
ATE478893T1 AT05763600T AT05763600T ATE478893T1 AT E478893 T1 ATE478893 T1 AT E478893T1 AT 05763600 T AT05763600 T AT 05763600T AT 05763600 T AT05763600 T AT 05763600T AT E478893 T1 ATE478893 T1 AT E478893T1
Authority
AT
Austria
Prior art keywords
therapeutic applications
genetically designed
designed cells
cells
genetically
Prior art date
Application number
AT05763600T
Other languages
English (en)
Inventor
Marc Penn
Matthew Kiedrowski
Original Assignee
Cleveland Clinic Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cleveland Clinic Foundation filed Critical Cleveland Clinic Foundation
Application granted granted Critical
Publication of ATE478893T1 publication Critical patent/ATE478893T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT05763600T 2004-05-19 2005-05-17 Genetisch hergestellte zellen für therapeutische anwendungen ATE478893T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57234904P 2004-05-19 2004-05-19
PCT/US2005/017050 WO2005116192A2 (en) 2004-05-19 2005-05-17 Genetically engineered cells for therapeutic applications

Publications (1)

Publication Number Publication Date
ATE478893T1 true ATE478893T1 (de) 2010-09-15

Family

ID=35451463

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05763600T ATE478893T1 (de) 2004-05-19 2005-05-17 Genetisch hergestellte zellen für therapeutische anwendungen

Country Status (9)

Country Link
US (3) US20050271639A1 (de)
EP (1) EP1763538B1 (de)
JP (1) JP5095403B2 (de)
CN (1) CN101065400A (de)
AT (1) ATE478893T1 (de)
AU (1) AU2005248352B2 (de)
CA (1) CA2567177C (de)
DE (1) DE602005023158D1 (de)
WO (1) WO2005116192A2 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003901668A0 (en) * 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
US20050271639A1 (en) * 2002-08-22 2005-12-08 Penn Marc S Genetically engineered cells for therapeutic applications
US20140170116A9 (en) * 2002-08-22 2014-06-19 Marc S. Penn Method of treating ischemic disorders
EP2361970A1 (de) * 2004-09-24 2011-08-31 Angioblast Systems Incorporated Verfahren zur Verbesserung der Vermehrung und/oder des Überlebens von Mesenchymalvorläuferzellen (MPC)
GB0514300D0 (en) * 2005-07-12 2005-08-17 Fond Ct San Raffaele Imflammation
US8168169B2 (en) * 2006-08-09 2012-05-01 Mclean Hospital Corporation Methods and compositions for the treatment of medical disorders
US7696309B2 (en) * 2006-10-23 2010-04-13 The Brigham And Women's Hospital, Inc. Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
WO2009074807A2 (en) * 2007-12-12 2009-06-18 Imperial Innovations Limited Methods
WO2009079451A2 (en) * 2007-12-14 2009-06-25 The Cleveland Clinic Foundation Compositions and methods of promoting wound healing
US20110165128A1 (en) * 2008-03-07 2011-07-07 Columbia University In The City Of New York Homing in mesenchymal stem cells
EP2411505A4 (de) 2009-03-26 2013-01-30 Univ California Mesenchymale stammzellen zur produktion hemmender rna zur krankheitsmodifikation
US20100247495A1 (en) * 2009-03-30 2010-09-30 Tom Ichim Treatment of Muscular Dystrophy
CA2772610C (en) 2009-08-28 2018-01-23 The Cleveland Clinic Foundation Sdf-1 delivery for treating ischemic tissue
AU2010306833A1 (en) * 2009-10-13 2012-05-10 Allocure Inc. Assay for the prediction of therapeutic effectiveness of mesenchymal stromal cells, and methods of using same
US9308277B2 (en) 2010-02-25 2016-04-12 Mesoblast International Sàrl Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
WO2012048298A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions
AU2012268078B2 (en) 2011-06-07 2017-06-01 Mesoblast International Sarl Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived Factor-1
EP2626369A1 (de) * 2011-11-24 2013-08-14 Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Gentechnisch veränderte mesenchymale Stammzellen und ihre therapeutische Verwendung
CA2873964A1 (en) * 2012-05-21 2013-11-28 Steven F. Dowdy Generation of human ips cells by a synthetic self-replicative rna
US20140065110A1 (en) 2012-08-31 2014-03-06 The Regents Of The University Of California Genetically modified msc and therapeutic methods
AU2014233229A1 (en) * 2013-03-15 2015-09-17 Juventas Therapeutics, Inc. Retrograde delivery of SDF-1 for treatment of myocardial infarction
EP3068867B1 (de) 2013-11-16 2018-04-18 Terumo BCT, Inc. Zellenexpansion in einem bioreaktor
JP2017500316A (ja) * 2013-12-13 2017-01-05 メソブラスト インターナショナル エスエイアールエル ストロマ細胞由来因子−１のプロテアーゼ耐性変異体を用いた、組織損傷を修復する方法
WO2015148704A1 (en) 2014-03-25 2015-10-01 Terumo Bct, Inc. Passive replacement of media
CN106715676A (zh) 2014-09-26 2017-05-24 泰尔茂比司特公司 按计划供养
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
WO2018184028A2 (en) 2017-03-31 2018-10-04 Terumo Bct, Inc. Cell expansion
US20190100730A1 (en) 2017-10-03 2019-04-04 Wallkill BioPharma, Inc. Treating diabetes with genetically modified beta cells
WO2019204509A2 (en) * 2018-04-18 2019-10-24 Summa Health Compositions and methods for the treatment of ischemia and cardiomyopathy
WO2020023806A1 (en) * 2018-07-25 2020-01-30 The Johns Hopkins University Compositions and methods for generation of heart field-specific progenitor cells
US20230149511A1 (en) * 2020-04-09 2023-05-18 Wallkill BioPharma, Inc. Treating autoimmune diseases with genetically modified cells
JP2024511064A (ja) 2021-03-23 2024-03-12 テルモ ビーシーティー、インコーポレーテッド 細胞捕獲及び増殖

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
EP0557459B1 (de) 1990-11-13 1997-10-22 Immunex Corporation Bifunktionelle wählbare fusionsgene
US5197985A (en) 1990-11-16 1993-03-30 Caplan Arnold I Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells
EP0804590A1 (de) 1993-05-21 1997-11-05 Targeted Genetics Corporation Bifunktionelle selektierbare fusionsgene auf dem cytosin-deaminase (cd) gen beruhend
US5602301A (en) * 1993-11-16 1997-02-11 Indiana University Foundation Non-human mammal having a graft and methods of delivering protein to myocardial tissue
US5591625A (en) 1993-11-24 1997-01-07 Case Western Reserve University Transduced mesenchymal stem cells
CN1136920C (zh) * 1995-02-28 2004-02-04 加利福尼亚大学董事会 基因转移介导的血管形成疗法
US6121246A (en) * 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
US5980887A (en) * 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells
US7393528B2 (en) * 1997-01-09 2008-07-01 Tvedten Stephen L Biological pesticide
CA2289665C (en) * 1997-06-13 2005-08-09 Genentech, Inc. Protein recovery by chromatography followed by filtration upon a charged layer
AU8401498A (en) * 1997-07-14 1999-02-10 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
MXPA00003885A (es) * 1997-10-22 2004-04-23 Inst Genetics Llc Quimiocinas con modificiaciones de la terminacion amino.
JP2002502608A (ja) * 1998-02-06 2002-01-29 コラテラル・セラピューティックス・インコーポレイテッド 血管新生促進因子である血管内皮細胞成長因子：ｖｅｇｆの変異体
US6676937B1 (en) * 1998-03-09 2004-01-13 Caritas St. Elizabeth's Medical Center Of Boston Inc. Compositions and methods for modulating vascularization
US20020107195A1 (en) * 1998-07-21 2002-08-08 Smithkline Beecham Corporation Method for inducing chemotaxis in endothelial cells by administering stromal cell derived factor-1alpha
IL125532A0 (en) * 1998-07-27 1999-03-12 Yeda Res & Dev Hematopoietic cell composition for use in transplantation
AU5241099A (en) * 1998-07-31 2000-02-21 Trustees Of Columbia University In The City Of New York, The Use of inhibitors of the activation of cxcr4 receptor by sdf-1 in treating rheumatoid arthritis
US7399751B2 (en) * 1999-11-04 2008-07-15 Sertoli Technologies, Inc. Production of a biological factor and creation of an immunologically privileged environment using genetically altered Sertoli cells
EP1169348B1 (de) * 1999-04-08 2016-02-24 The General Hospital Corporation Erwünschte bewegung von menschlichen migrierenden zellen weg von einer substanzquelle
US7125856B1 (en) * 1999-04-15 2006-10-24 St. Elizabeth's Medical Center Of Boston, Inc. Angiogenic growth factors for treatment of peripheral neuropathy
US6358697B2 (en) * 1999-04-21 2002-03-19 Children's Hospital Medical Center Intracellular pharmaceutical targeting
JP5414958B2 (ja) * 2000-06-05 2014-02-12 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク ヒト骨髄由来内皮前駆細胞の同定、及び虚血性傷害後の心筋細胞の機能を改善するためのヒト骨髄由来内皮前駆細胞の使用
WO2002009650A2 (en) * 2000-07-31 2002-02-07 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
US7402567B2 (en) * 2000-10-27 2008-07-22 The Regents Of The University Of California Treatment of disease by inducing cell apoptosis
WO2002036078A2 (en) * 2000-11-05 2002-05-10 University Of Florida Targeting pluripotent stem cells to tissues
EP1334177B1 (de) * 2000-11-14 2005-01-26 Université Libre de Bruxelles Herstellung und verwendung von dendritischen zellen
JP2004517078A (ja) * 2000-12-01 2004-06-10 シェーリング　コーポレイション 哺乳動物遺伝子および関連試薬の使用
US7399740B2 (en) * 2001-06-28 2008-07-15 Yeda Research And Development Co. Ltd. Poly-Glu,Tyr for neuroprotective therapy
US20040235160A1 (en) * 2001-08-07 2004-11-25 Mitsuo Nishikawa Process for preparing hematopoietic stem cells
AR036401A1 (es) * 2001-09-14 2004-09-08 Stem Cell Therapeutics Inc Incremento de la cantidad de celulas madre neuronales inducido por prolactina.
US7402724B2 (en) * 2002-01-04 2008-07-22 Mayo Foundation For Medical Education And Research Longevity and PAPP-A
AU2002226683A1 (en) * 2002-01-17 2003-07-30 Cardio Incorporated Complex therapy for tissue regeneration
US7396537B1 (en) * 2002-02-28 2008-07-08 The Trustees Of The University Of Pennsylvania Cell delivery patch for myocardial tissue engineering
AU2003225791A1 (en) * 2002-03-15 2003-09-29 Department Of Veterans Affairs, Rehabilitation R And D Service Methods and compositions for directing cells to target organs
US20030199464A1 (en) * 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
US20040037811A1 (en) * 2002-08-22 2004-02-26 The Cleveland Clinic Foundation Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration in ischemic cardiomyopathy
US20140170116A9 (en) * 2002-08-22 2014-06-19 Marc S. Penn Method of treating ischemic disorders
US20050271639A1 (en) * 2002-08-22 2005-12-08 Penn Marc S Genetically engineered cells for therapeutic applications
JP2004099471A (ja) * 2002-09-05 2004-04-02 Cardio Corp 心筋梗塞および心不全の治療薬
JP2006505380A (ja) * 2002-11-05 2006-02-16 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 間葉幹細胞およびその使用方法
EP1583422B1 (de) * 2002-12-05 2016-03-30 Case Western Reserve University Ischämie-therapien auf zellgrundlage
AU2003902037A0 (en) * 2003-04-24 2003-05-15 Mclachlan, Craig Method for tissue growth
US7396680B2 (en) * 2003-10-31 2008-07-08 Cornell Research Foundation, Inc. Stem cell-specific promoters and their use
IL158868A0 (en) * 2003-11-13 2004-05-12 Yeda Res & Dev Methods of generating and using stem cells enriched with immature primitive progenitor
US20060105950A1 (en) * 2004-10-25 2006-05-18 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Morphogen compositions and use thereof to treat wounds
WO2006083394A2 (en) * 2004-12-21 2006-08-10 Ethicon, Inc. Postpartum cells derived from placental tissue, and methods of making, culturing, and using the same
US20070173471A1 (en) * 2006-01-24 2007-07-26 Losordo Douglas W Morphogen compositions and methods of use thereof to treat heart disorders
US7405195B2 (en) * 2006-03-27 2008-07-29 Natural Beauty Bio-Technology Limited Cosmetic compositions
WO2009079451A2 (en) * 2007-12-14 2009-06-25 The Cleveland Clinic Foundation Compositions and methods of promoting wound healing
CA2772610C (en) * 2009-08-28 2018-01-23 The Cleveland Clinic Foundation Sdf-1 delivery for treating ischemic tissue

Also Published As

Publication number Publication date
AU2005248352B2 (en) 2009-07-30
US20070224171A1 (en) 2007-09-27
AU2005248352A1 (en) 2005-12-08
US20050271639A1 (en) 2005-12-08
EP1763538A2 (de) 2007-03-21
CN101065400A (zh) 2007-10-31
CA2567177C (en) 2011-08-09
US20070258943A1 (en) 2007-11-08
WO2005116192A3 (en) 2006-04-13
DE602005023158D1 (de) 2010-10-07
JP2007537752A (ja) 2007-12-27
WO2005116192A2 (en) 2005-12-08
JP5095403B2 (ja) 2012-12-12
CA2567177A1 (en) 2005-12-08
EP1763538B1 (de) 2010-08-25

Similar Documents

Publication Publication Date Title
ATE478893T1 (de) Genetisch hergestellte zellen für therapeutische anwendungen
AR105435A2 (es) Método de recombinación homóloga intramolecular en el genoma de una célula vegetal
WO2010141801A3 (en) Reprogramming t cells and hematophietic cells
ATE530638T1 (de) Pluripotente autologe stammzellen aus der mündlichen oder gastrointestinalen schleimhaut
AR069168A1 (es) Variantes de alfa -amilasas con propiedades alteradas
MY159971A (en) Multipotent/pluripotent cells and methods
EA201270187A1 (ru) Ферментативное продуцирование этанола, не содержащего глицерин
ES2570382T3 (es) Composiciones y métodos para la producción de azúcares fermentables
CA2811364C (en) Methods and compositions for inhibiting viral entry into cells
BR112012015576A2 (pt) "cerâmica de vidro de dissilicato de lítio, método para sua fabricação e seu uso"
BR112013002811A8 (pt) meios básicos simplificados para cultura celular pluripotente de humano
ES2571757T3 (es) Microorganismos con rango de utilización de sustrato ampliado
TW200608991A (en) Chemokine combinations to mobilize progenitor/stem cells
NZ600585A (en) Expression of hexose kinase in recombinant host cells
SG196784A1 (en) Stem cell cultures
EP1915440A4 (de) Zusammensetzungen von mit kombinationen verschiedener stamm- und vorläuferzellpopulationen angereicherten zellen, verfahren zur verwendung davon und verfahren zur erstellung privater banken davon
EA201492273A1 (ru) Композиции полимера мирцена
CY1107014T1 (el) Χρηση θρεπτικου μεσου κυτταροκαλλιεργειας ελευθερου ορου για την παραγωγη il-18bp σε κυτταρα θηλαστικων
PE20130213A1 (es) Marcadores predictivos utiles en el tratamiento del sindrome fragil x (fxs)
ATE536914T1 (de) Spezifische cd4+cd25+-regulatorische t-zellen für die hämatopoetische zelltransplantation und immuntoleranz
CY1120800T1 (el) Μεθοδοι και συνθεσεις για την in vivo ενεργοποιηση του σχηματισμου παγκρεατικων βητα κυτταρων
EP2558124A4 (de) Polysaccharidzusammensetzungen und verfahren zu ihrer verwendung zur behandlung und prävention von mit vorläuferzellenmobilisierung assoziierten erkrankungen
MX2020005849A (es) Células madre y progenitoras hematopoyéticas humanas cd34+ modificadas con crispr-cas9 y sus usos.
WO2012088225A3 (en) Method for identifcation and culture of multipotent mesenchymal stem cells with high proliferation potential
WO2010059876A3 (en) In vitro human b lymphopoiesis culture system

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties